The experience of using agomelatine (Valdoxan) in the treatment of generalised anxiety disorder
https://doi.org/10.14412/2074-2711-2025-4-104-109
Abstract
Generalised anxiety disorder (GAD) is one of the most common anxiety disorders worldwide. Without treatment, GAD is characterised by a chronic course and significantly impairs social and occupational functioning. The main method of treating GAD in clinical practice is psychopharmacotherapy. Despite the fact that psychiatrists have a fairly large number of psychotropic drugs at their disposal, which are used in accordance with international and domestic clinical guidelines for the treatment of GAD, a number of therapeutic aspects remained unresolved until recently.
In the updated clinical guidelines, agomelatine, an antidepressant that acts on melatonergic (MT1, MT2) and serotonergic (5-HT2C) receptors, was included among the first-line drugs for the treatment of GAD. The efficacy of agomelatine in treating GAD symptoms has been demonstrated in a number of randomised clinical trials. This article presents our own observations, illustrating some aspects of the use of agomelatine in real clinical practice.
Supporting agencies: The article is sponsored by Servier
About the Author
V. I. Frolova
Patrice Lumumba Peoples' Friendship University of Russia (RUDN University)
Russian Federation
Competing Interests:
Russian Federation
Veronika Igorevna Frolova - Department of Psychiatry, Psychotherapy and Psychosomatic Pathology, Faculty of Continuing Medical Education, Medical Institute
6, Miklukho-Maklaya St., Moscow 117198
Competing Interests:
The conflict of interests did not affect the results of the study
References
1. Remes O, Brayne C, van der Linde R, Lafortune L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav. 2016. Jun 5;6(7):e00497. doi: 10.1002/brb3.497
2. Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry. 2009;70 Suppl 2:4-9.
3. Generalized anxiety disorder. Clinical guidelines. 2024–2026 (19.09.2024). Available at: https://cr.minzdrav.gov.ru/view-cr/457_3 (accessed 24.12.2024) (In Russ.).
4. Neznanov NG, Martynikhin IA, Mosolov SN. Diagnosis and treatment of Anxiety Disorders in Russia: The Results of a Web-based Survey of Psychiatrists. Sovremennaya terapiya psikhicheskikh rasstroystv = Current Therapy of Mental Disorders. 2017;(2):2-13. doi: 10.21265/PSYPH.2017.41.6437 (In Russ.).
5. Kostyukova EG. Generalized Anxiety Disorder: Basics of Diagnosis, Therapy and Problems Specific to Russia. Sovremennaya terapiya psikhicheskikh rasstroystv = Current Therapy of Mental Disorders. 2024;(2):23-31. doi: 10.21265/PSYPH.2024.31.31.003 (In Russ.).
6. Medvedev VE. Agomelatine for the Treatment of Generalized Anxiety Disorder. Sovremennaya terapiya psikhicheskikh rasstroystv = Current Therapy of Mental Disorders. 2024;(4):55-65. doi: 10.21265/PSYPH.2024.47.73.006 (In Russ.).
7. Mosolov SN, Alfimov PV. Algorithm for biological treatment of Generalized Anxiety Disorder. Sovremennaya terapiya psikhicheskikhrasstroystv = Current Therapy of Mental Disorders. 2015;(2):24-8 (In Russ.).
8. Medvedev VE, Kotova OV, Akarachkova ES, et al. Generalized anxiety disorder: anatomical and functional features of the brain. Aviandr – new possibilities of therapy. Sovremennaya terapiya v psikhiatrii i nevrologii = Modern Therapy in Psychiatry and Neurology. 2024;(2):14-20 (In Russ.).
9. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebocontrolled study. J Clin Psychopharmacol. 2008 Oct;28(5):561-6. doi: 10.1097/JCP.0b013e318184ff5b
10. Stein DJ, Ahokas A, Marquez MS, et al. Agomelatine in Generalized Anxiety Disorder: An Active Comparator and PlaceboControlled Study. J Clin Psychiatry. 2014;75(4):362-8. doi: 10.4088/JCP.13m08433
11. Stein DJ, Ahokas A, Albarran C, et al Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry. 2012 Jul;73(7):1002-8. doi: 10.4088/JCP.11m07493
Review
For citations:
Frolova VI. The experience of using agomelatine (Valdoxan) in the treatment of generalised anxiety disorder. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(4):104-109. (In Russ.) https://doi.org/10.14412/2074-2711-2025-4-104-109
Views:
16
Email this article 